[Skip to Content]
[Skip to Content Landing]
Editorial
September 26, 2017

Pharmacogenomic Testing and WarfarinWhat Evidence Has the GIFT Trial Provided?

Author Affiliations
  • 1Department of General Practice and Centre for Cancer Research, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Australia
JAMA. 2017;318(12):1110-1112. doi:10.1001/jama.2017.11465

Warfarin is the most widely prescribed anticoagulant worldwide and is a significant cause of emergency department visits and hospitalizations. Warfarin has a narrow therapeutic index and wide variation in dose requirements among patients, partially due to diet, comorbidities, and interactions with other medications. These factors create clinical challenges of underdosage or overdosage, with concomitant risk of thrombosis or bleeding, both of which can be reduced by careful monitoring using the international normalized ratio (INR) phenotypic biomarker.

First Page Preview View Large
First page PDF preview
First page PDF preview
×